Skip to search formSkip to main contentSkip to account menu

LY2801653

Known as: LY-2801653 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Merestinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract A07: Mst1r inhibition with LY2801653 increases survival in mice bearing aggressive pancreatic adenocarcinoma organoid model
Background: RON/MST1R is a receptor tyrosine kinase variably expressed in epithelial cells and macrophages and overexpressed in… 
2017
2017
Abstract 1823: Characterization of the anti-angiogenic properties of merestinib (LY2801653), an oncokinase inhibitor
Merestinib (LY2801653) is an orally bioavailable small molecule inhibitor of several oncokinases, including MET, AXL, DDR1/2… 
2016
2016
MET inhibition and merestinib (LY-2801653) for cancer treatment
2016
2016
Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing…
In cancer, the formation of chimeric gene fusions by genomic rearrangement causes aberrant receptor tyrosine kinase activation… 
2014
2014
Abstract CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Aberrant MET signaling, whether due to genetic… 
2014
2014
Small Cell Lung Cancer - Inhibitor LY2801653 in Non Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule
Lung cancer is a heterogeneous disease encompassing a wide array of genetic abnormalities. The MET receptor tyrosine kinase is… 
2013
2013
Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Under normal conditions MET receptor activation… 
2013
2013
Cancer Therapy : Preclinical Inhibition of Tumor Growth andMetastasis in Non – Small Cell Lung Cancer by LY 2801653 , an Inhibitor of Several Oncokinases , Including MET
Purpose: Lung cancer is the leading cause of cancer-related death worldwide. Sustained activation, overexpression, or mutation of… 
2010
2010
Abstract 3611: LY2801653, an orally available small molecule inhibitor of c-Met, demonstrated broad antitumor efficacy in patient derived xenograft models
The receptor tyrosine kinase c-Met and its ligand hepatocyte growth factor (HGF) play important roles in cell growth, migration… 
2010
2010
Abstract 4511: LY2801653 treatment increases survival of mice bearing H441 orthotopic lung tumors
Lung cancer is the leading cause of cancer-related death for both men and women in the world. c-Met receptor tyrosine kinase (RTK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)